Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colorectal Neoplasms 36Stomach Neoplasms 9Colonic Neoplasms 6Rectal Neoplasms 3Sarcoma 2Carcinoma, Hepatocellular 2Advanced Colorectal Carcinoma 2Unresectable Metastatic Colorectal Cancer 1Platinum Resistant Ovarian Cancer 1Patients With Advanced Metastatic Colorectal Cancer 1Pancreatic Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1NSCLC 1Metastatic Colorectal Adenocarcinoma 1Metastasis Colorectal Cancer 1Lung Neoplasms 1Locally Advanced Rectal Cancer 1Gastric/Gastroesophageal Junction Adenocarcinoma 1Gastric Cancer Adenocarcinoma Metastatic 1Fruquintinib 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Cancer Metastatic 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Adenocarcinoma 1Advanced Solid Tumors 1Advanced Pancreatic Carcinoma 1Advanced Gastric Cancer 1

Interventions

Paclitaxel 2Injections 2toripalimab 1tislelizumab 1surufatinib 1sotorasib 1osimertinib 1netrin-1 inhibitor NP137 1lazertinib 1fluzoparib 1camrelizumab 1Panitumumab 1PM 01183 1Nivolumab 1Ipilimumab 1HMPL-013 1Erlotinib Hydrochloride 1Dexamethasone 1Calcium Dobesilate 1Bortezomib 1Bevacizumab 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Solid Tumors × HMPL-013 × Clear all
NCT04716634 2025-03-25

Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

BeiGene

Phase 2 Completed
84 enrolled 17 charts
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡